Eledon Pharmaceuticals Inc (ELDN)
$2.54
Performance
- $2.43$2.60$2.54
4.33%
Downside
Day's Volatility :6.54%
Upside
2.31%
- $1.07$3.35$2.54
57.87%
Downside
52 Weeks Volatility :68.05%
Upside
24.16%
Returns
| Period | Eledon Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -8.63% | 0.0% |
6 Months | 47.67% | 0.0% |
1 Year | 89.55% | 0.0% |
3 Years | -68.01% | -22.3% |
Highlights
Market Capitalization | 102.3M |
Book Value | - $0.22 |
Earnings Per Share (EPS) | 0.42 |
PE Ratio | 6.14 |
Wall Street Target Price | 14.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -25.8% |
Return On Equity TTM | -70.71% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -36.9M |
Diluted Eps TTM | 0.42 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.68 |
EPS Estimate Next Year | -1.2 |
EPS Estimate Current Quarter | -0.3 |
EPS Estimate Next Quarter | -0.29 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 451.18%
Technicals Summary
Sell
Neutral
Buy
Eledon Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Eledon Pharmaceuticals Inc | -2.31% | 47.67% | 89.55% | -68.01% | -83.18% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Eledon Pharmaceuticals Inc | 6.14 | 6.14 | NA | -1.68 | -0.71 | -0.26 | NA | -0.22 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Eledon Pharmaceuticals Inc | Buy | $102.3M | -83.18% | 6.14 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Eledon Pharmaceuticals Inc
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 137.2%
Institutional Holdings
Bvf Inc
15.87%Armistice Capital, LLC
5.89%Zimmer Partners LP
5.32%Vanguard Group Inc
2.79%Woodline Partners LP
1.70%Nantahala Capital Management, LLC
1.51%
Company Information
eledon pharmaceuticals, inc. is a clinical stage biotechnology company using its expertise in targeting the cd40l pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. our lead program, at-1501, is a potential best-in-class humanized igg1 anti-cd40l antibody with high affinity for cd40l, a well-validated biological target with broad therapeutic potential. the cd40/cd40l pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.
Organization | Eledon Pharmaceuticals Inc |
Employees | 20 |
CEO | Dr. David-Alexandre C. Gros M.D., Ph.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$2.54
-1.17%
Keyarch Acquisition Corp
$2.54
-1.17%
Connexa Sports Technologies Inc
$2.54
-1.17%
Us Value Etf
$2.54
-1.17%
First Wave Biopharma Inc
$2.54
-1.17%
Global X Msci Next Emerging
$2.54
-1.17%
Fat Projects Acquisition Corp
$2.54
-1.17%
Capital Link Global Fintech
$2.54
-1.17%
Applied Uv Inc
$2.54
-1.17%